- Home
- SNTI vs NCRA Comparison
SNTI vs NCRA Comparison
Compare SNTI & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- NCRA
- Stock Information
- Founded
- SNTI 2016
- NCRA 2002
- Country
- SNTI United States
- NCRA Taiwan
- Employees
- SNTI N/A
- NCRA N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- NCRA Farming/Seeds/Milling
- Sector
- SNTI Health Care
- NCRA Consumer Staples
- Exchange
- SNTI Nasdaq
- NCRA Nasdaq
- Market Cap
- SNTI 14.1M
- NCRA 15.4M
- IPO Year
- SNTI N/A
- NCRA N/A
- Fundamental
- Price
- SNTI $2.12
- NCRA $1.11
- Analyst Decision
- SNTI
- NCRA
- Analyst Count
- SNTI 0
- NCRA 0
- Target Price
- SNTI N/A
- NCRA N/A
- AVG Volume (30 Days)
- SNTI 24.1K
- NCRA 6.1K
- Earning Date
- SNTI 11-11-2024
- NCRA 08-14-2024
- Dividend Yield
- SNTI N/A
- NCRA N/A
- EPS Growth
- SNTI N/A
- NCRA N/A
- EPS
- SNTI N/A
- NCRA N/A
- Revenue
- SNTI $338,000.00
- NCRA $26,403,874.00
- Revenue This Year
- SNTI $254.47
- NCRA N/A
- Revenue Next Year
- SNTI $169.66
- NCRA N/A
- P/E Ratio
- SNTI N/A
- NCRA N/A
- Revenue Growth
- SNTI N/A
- NCRA 33.73
- 52 Week Low
- SNTI $1.52
- NCRA $0.73
- 52 Week High
- SNTI $8.48
- NCRA $1.60
- Technical
- Relative Strength Index (RSI)
- SNTI 36.91
- NCRA 54.58
- Support Level
- SNTI $2.08
- NCRA $1.06
- Resistance Level
- SNTI $2.56
- NCRA $1.20
- Average True Range (ATR)
- SNTI 0.26
- NCRA 0.10
- MACD
- SNTI -0.04
- NCRA -0.00
- Stochastic Oscillator
- SNTI 14.12
- NCRA 61.29
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.